Studies have been small and often not great. The best info so far says don’t use it, get vaccinated, and hang in there for the more promising meds being tested.
EDWARD MILLS CAME to the meeting last month with very good data. A clinical trials expert at McMaster University, Mills was presenting new results from a trial that is looking at how well half a dozen different drugs treat Covid-19—not for the people so sick they’re in the emergency room or the hospital, but in people whose symptoms haven’t gotten that bad yet. People sick at home, in other words.
At his online talk, put on by the National Institutes of Health, Mills’ slides told the tale: A relatively safe, familiar, cheap drug reduced the relative risk of mild Covid getting worse by nearly 30 percent. The drug is fluvoxamine, a selective serotonin reuptake inhibitor—an antidepressant. (It’s also an anti-inflammatory, and inflammation and an overreacting immune system are hallmarks of serious Covid infection, so that might be why it seems to help). Get a bunch of people with Covid and randomize them into two groups; 739 get fluvoxamine and 733 get a placebo. Only 77 of the fluvoxamine-takers end up in the hospital; 109 of the placebo group do. This is exciting.